UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Checkpoint is implementing good security practices.
Checkpoint Therapeutics, Inc. (�Checkpoint�) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, in a Phase 1/2 clinical trial for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (�NSCLC�). In addition, Checkpoint is currently evaluating its lead antibody product candidate, CK-301, an anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in a Phase 1 clinical trial in checkpoint therapy-na�ve patients with selected recurrent or metastatic cancers. Checkpoint plans to develop CK-301 as a treatment for patients with NSCLC and other solid tumors. Checkpoint is a majority-controlled subsidiary of Fortress Biotech, Inc., and is headquartered in New York City.
This report shows a preliminary security rating for Checkpoint. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.Get a deeper scan →
Read more about the latest issues in cybersecurity
The dark web is a collection of websites that exist on encrypted darknet, overlay networks that ...
Cross-site scripting (XSS) is a type of security vulnerability typically found in web applications. ...
Compare Checkpoint's security performance with other companies